Project Grant HT94252310737

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Faknostics LLC a $651,952 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop novel peptidic inhibitors targeting the paxillin-FAK (Focal Adhesion Kinase) interaction for the treatment of liver fibrosis. The project aims to optimize lead peptide candidates, characterize their in vitro performance, and confirm efficacy in an animal model of liver...

The U.S. Department of Health and Human Services' National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $361,400 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oncotrap Inc. The funding supports the development of a bispecific single-domain antibody targeting the chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis (NASH). The award will enable Oncotrap to generate a human version...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $399,966 to Cloverleaf Bio, Inc. to advance the pre-clinical development of a novel therapeutic approach for treating hepatocellular carcinoma (HCC), the most common form of liver cancer. The research aims to develop engineered transfer RNAs (tRNAs) containing the chemotherapeutic agent 5-fluorouracil (5-FU) that can irreversibly inhibit multiple tRNA-modifying enzymes, a vulnerability of...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,391,142 to Function Therapeutics Inc. to develop small molecule PAR1 ligands as a novel treatment approach for metabolic dysfunction-associated steatohepatitis (MASH). The project aims to synthesize and evaluate novel "Parmodulin" compounds that can shift PAR1 signaling in...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $687,679 aims to functionally characterize the transcriptional regulatory landscape of hepatocellular carcinoma (HCC) in order to uncover novel tumor cell-intrinsic vulnerabilities. The research plan involves computationally establishing human HCC transcriptional master regulators (TMRs), validating their tumor cell-intrinsic functions using CRISPR interference and activation...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $793,324 to the Beckman Research Institute of the City of Hope to discover and validate CYP8B1 inhibitors as potential treatments for hepatocellular carcinoma (HCC). The project aims to: 1) identify CYP8B1 inhibitors through high-throughput screening of a 250,000-compound library; 2) validate hit compounds for potency, specificity, and structure-activity relationships; and 3)...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $293,543 to Furanica, Inc. to develop a novel compound, FAL-113, for the treatment of nonalcoholic steatohepatitis (NASH). The project aims to determine the mechanism of action, pharmacokinetics, and pharmacological efficacy of FAL-113 in preclinical NASH models. FAL-113 is designed to simultaneously modulate...

This Project Grant award from the National Cancer Institute (CFDA Program 93.396 - Cancer Biology Research) totaling $2,397,277 will support research at the Sanford Burnham Prebys Medical Discovery Institute to investigate the role of metabolic stress and hypernutrition in the progression from non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC). The research will focus on understanding how interactions between cellular signaling pathways (NRF2, ATF6) and mitochondrial...

This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $938,470 to the University of Massachusetts Medical School to investigate a novel adipokine that may resolve non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in mouse models. The award period runs from September 1, 2024 to June 30, 2028. The research aims...